New developments in the treatment of nausea and vomiting caused by chemotherapy;Nieuwe ontwikkelingen in de behandeling van misselijkheid en braken door chemotherapie

Nederlands Tijdschrift voor Geneeskunde

Volumn 147, Issue 15, 2003, Pages 690-694

  De Wit, R ^a   Van Alphen, M M A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; APREPITANT; CISPLATIN; CYTOSTATIC AGENT; DEXAMETHASONE; DOLASETRON MESILATE; GRANISETRON; NEUROKININ 1 RECEPTOR; NEUROKININ 1 RECEPTOR ANTAGONIST; ONDANSETRON; PLACEBO; SEROTONIN 3 ANTAGONIST; TROPISETRON;

ARTICLE; CANCER CHEMOTHERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; DRUG RECEPTOR BINDING; DRUG TARGETING; DRUG UTILIZATION; HUMAN; NAUSEA AND VOMITING; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PROGNOSIS; PROTECTION; SYMPTOM;

ANTIEMETICS; ANTINEOPLASTIC AGENTS; DEXAMETHASONE; DRUG THERAPY, COMBINATION; HUMANS; NAUSEA; RECEPTORS, NEUROKININ-1; SEROTONIN ANTAGONISTS; TIME FACTORS; VOMITING;

EID: 0037433663     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, et al. Recommendations for the use of antiemetics: evidence-based clinical practice guidelines. J Clin Oncol 1999;17:2971-94.
2. Verweij J, Wit de R, Mulder de PHM. Optimal control of acute cisplatin induced emesis. Oncology 1996;53(Suppl 1):56-64.
3. Roila F, Donati D, Tamberi S, Margutti G. Delayed emesis: incidence, pattern, prognostic factors and optimal treatment. Supp Care Cancer 2002;10:88-95.
4. Coates A, Abraham S, Kaye SB, Schwerbutts T, Frewin CH, Fox RH, et al. On the receiving end - patient perception of the side effects of cancer chemotherapy. Eur J Cancer Clin Oncol 1983;19:203-8.
5. Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, et al. Prevention of cisplatin-indiced emesis. A double-blind multicenter randomised cross-over study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 1991;9:675-8.
6. Smyth JF, Coleman RE, Nocilson M, Gallmeier WM, Leonard RCF, Cornbleet MA, et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 1991;303:1423-6.
7. Smith DB, Newlands ES, Rustin GJS, Begent RHJ, Howells N, McQuade B, et al. Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 1991;338:487-90.
8. Wit R de, Boer AC de, Linden GHM van de, Stoter G, Sparreboom A, Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomised double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. J Clin Oncol [ter perse].
9. 3 antagonists; a pilot study. J Cancer Res Clin Oncol 1995;121:126-7.
10. Tsukada H, Hirose T, Yokoyama A, Kurita Y. Randomised comparison of ondansetron plus dexamethasone with dexamethasone alone for the control of delayed cisplatin-induced emesis. Eur J Cancer 2001;37:2398-404.
11. Gandara DR. Progress in the control of acute and delayed emesis induced by cisplatin. Eur J Cancer 1991;27(Suppl 1):9-11.
12. Jones AL, Hill AS, Soukop M, Hutcheon AW, Cassidy J, Kaye SB, et al. Comparison of dexamethasone and ondansetron in the profylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 1991;338:384-7.
13. Navari RM, Madajewicz S, Anderson N, Tchekmedyian NS, Whaley W, Garewal H, et al. Oral ondansetron for the control of cisplatin-induced delayed emesis: a large, multicenter, double-blind, randomised comparative trial of ondansetron versus placebo. J Clin Oncol 1995;13:2408-16.
14. Latreille J, Pater J, Johnston D, Laberge F, Stewart D, Rusthoven J, et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. J Clin Oncol 1998;16:1174-8.
15. Goedhals L, Heron J-F, Kleisbauer J-P, Pagani O, Sessa C. Control of delayed nausea and vomiting with granisetron plus dexamethasone or dexamethasone alone in patients receiving highly emetogenic chemotherapy: a double-blind, placebo-controlled, comparative study. Ann Oncol 1998;9:661-6.
16. The Italian Group for Antiemetic Research. Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 1995;332:1-5.
17. 3 antagonists. Br J Cancer 1997;76:1055-61.
18. 3 antagonists prophylaxis is not maintained. J Clin Oncol 1996;14:644-51.
19. Wit R de, Berg H van der, Burghoudts J, Nortier J, Slee P, Rodenburg C, et al. Initial high anti-emetic efficacy of granisetron with dexamethasone is not maintained over repeated cycles. Br J Cancer 1998;77:1487-91.
20. Holzer P, Schluet W, Maggi CA. Substance P stimulates and inhibits peristalsis via distinct receptors. J Pharmacol Exp Ther 1995;274:322-8.
21. Rudd JA, Jordan CC, Naylor RJ. The action of the NK, tachykinin receptorantagonist, CP 99,994, in antagonizing the acute and delayed emesis induced by cisplatin in the ferret. Br J Pharmacol 1996;119:931-6.
22. Kris MG, Radford JE, Pizzo BA, Inabinet R, Hesketh A, Hesketh PJ. Use of an NKI receptor antagonist to prevent delayed emesis after cisplatin. J Nat Cancer Inst 1997;89:817-8.
23. Hesketh PJ, Gralla RJ, Webb RT, Ueno W, DelPrete S, Bachinsky ME, et al. Randomized phase II study of the neurokinin I receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis. J Clin Oncol 1999;17:338-43.
24. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A, et al. Reduction of cisplatin-induced emesis by a selective neurokinin-I-receptor antagonist. N Engl J Med 1999;340:190-5.
25. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C, et al. Prevention of cisplatin-induced emesis by the oral neurokinin-I antagonist, MK-879, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol 2001;19:1759-67.
26. Wit R de, Herrstedt J, Rapoport BL, Elmer M, Schmidt C, Carides A, et al. Maintenance of protection against chemotherapy induced nausea and vomiting in multiple cycles with the oral NKI antagonist MK-869. Alexandria: American Society of Clinical Oncology; 2002. p. 367.